...
mtva-img

MetaVia Inc., Common Stock

MTVA

NAQ

$1.6

-$0.16

(-9.09%)

1D

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$0
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
149.44K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.55 L
$6.75 H
$1.6

About MetaVia Inc., Common Stock

MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. more

Returns

Data is not properly formatted.

Ratios

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MTVA
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MTVA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.00
EV/R 0.00
EV/Ebitda NM

FAQs

What is MetaVia Inc. share price today?

MetaVia Inc. (MTVA) share price today is $1.6

Can Indians buy MetaVia Inc. shares?

Yes, Indians can buy shares of MetaVia Inc. (MTVA) on Vested. To buy MetaVia Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MTVA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of MetaVia Inc. be purchased?

Yes, you can purchase fractional shares of MetaVia Inc. (MTVA) via the Vested app. You can start investing in MetaVia Inc. (MTVA) with a minimum investment of $1.

How to invest in MetaVia Inc. shares from India?

You can invest in shares of MetaVia Inc. (MTVA) via Vested in three simple steps:

  • Click on Sign Up or Invest in MTVA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in MetaVia Inc. shares
What is MetaVia Inc. 52-week high and low stock price?

The 52-week high price of MetaVia Inc. (MTVA) is $6.75. The 52-week low price of MetaVia Inc. (MTVA) is $1.55.

What is MetaVia Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of MetaVia Inc. (MTVA) is

What is MetaVia Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of MetaVia Inc. (MTVA) is 0.00

What is MetaVia Inc. dividend yield?

The dividend yield of MetaVia Inc. (MTVA) is 0.00%

What is the Market Cap of MetaVia Inc.?

The market capitalization of MetaVia Inc. (MTVA) is

What is MetaVia Inc.’s stock symbol?

The stock symbol (or ticker) of MetaVia Inc. is MTVA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top